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COST IMPACT ANALYSIS OF USING THE IMPROVE® TOOL FOR VENOUS 
THROMBOEMBOLISM RISK ASSESSMENT IN MEDICAL PATIENTS ADMITTED TO THE 
UK NHS HOSPITALS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION 
OBJECTIVES: To estimate the cost impact of using IMPROVE® venous thromboembolism 
(VTE) risk assessment tool, for medical admissions (MAs) to the UK National Health Service 
(NHS) hospitals, compared to Department of Health National tool. 
 
METHODS: Cost impact analysis was undertaken. Speciality (HRG) codes for MAs and 
number of bed-days for those with length of stay>3 days were identified in Hospital Episode 
Statistics data (2015/16). The percentage of MAs that are assessed as at high risk of VTE, 
using each tool, were estimated using literature review and expert opinion. Prophylaxis 
cost/bed-day was calculated and multiplied by the difference in the number of bed-days. 
Result were adjusted for potential cost increase due to increased VTE incidence. 
Implementation costs were not included. 
 
RESULTS: Based on the literature review, 80% and 40% of MAs would require prophylaxis 
when using the National tool and IMPROVE® tool, respectively. The total number of bed-
days for MAs, with a length of stay of 3 days or more, was 18.8 million. The cost of 
prophylaxis per bed-day was £3.03 (cost year 2016). At the National tool intervention rate of 
80%, the total cost of prophylaxis is approximately £45.5 Million. At IMPROVE® tool 
intervention rate of 40%, after adjusting for a small increase in VTE events, the net annual 
saving from the reduction in prophylaxis was estimated to be around £22 Million. 
 
CONCLUSIONS: Using IMPROVE® tool for VTE risk assessment in medical patients 
admitted to UK NHS hospitals may lead to substantial cost saving over the currently used 
risk assessment tool. However, the costs of implementation have not been included in this 
analysis. Additionally, IMPROVE® tool has not been validated in the UK. Overall, the choice 
of a VTE risk assessment tool should not only take into account cost impact but also other 
factors including validity in the target population. 
